Bristol-Myers Squibb Co. and Sanofi-Aventis are anxiously awaiting the outcome of an antitrust review of a proposed patent settlement with Apotex Inc. over the timing of a generic launch of clopidogrel (Plavix).
The March settlement would all but guarantee that Plavix remains free of generic competition through 2011. But if antitrust regulators...




